ONWARD 220

Phase 2 Basket Trial in PR+ Gynecologic Cancers

ONWARD 220 will evaluate Apristor in 2L/3L chemotherapy resistant uterine (endometrial) and ovarian (low grade serous, granulosa) cancer patients.

To learn more →

ONWARD 203

Window of Opportunity Trial in PR+ Breast Cancer

ONWARD 203 will evaluate Apristor in a presurgical, window of opportunity study in treatment naive PR+ breast cancer patients.

To learn more →

 

ONWARD 201

Phase 2 Trial in ER+, PR+, HER2- Breast Cancer

ONWARD 201 will evaluate Apristor + Faslodex in second line (2L) metastatic breast cancer patients who are ER+, PR+, HER2- and who have failed first line Cdk4/6 inhibitor plus antiestrogen combination therapy.

To learn more →

Investigator Sponsored Trials

Join our Investigator Network

At Context Therapeutics, we are committed to the advancement of medical and scientific knowledge that addresses the unmet needs of patients with hormone driven cancers.  

Submit an IST →

 

PHYSICIANS: Click here to learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts.